Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: HCA stock price vs ACAD: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at ACAD's multiple
Needs ACAD P/E.
Implied fair value · at HCA's multiple
Needs HCA P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Ten period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
HCA Healthcare, Inc. · implied price per share
Bear
$130.81
Base
$187.37
Bull
$261.03
ACADIA PHARMACEUTICALS INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
LABCORP HOLDINGS INC.
HCA vs LH
WEST PHARMACEUTICAL SERVICES INC
HCA vs WST
BAXTER INTERNATIONAL INC
HCA vs BAX
MCKESSON CORP
HCA vs MCK
Cigna Group
HCA vs CI
UNITEDHEALTH GROUP INC
HCA vs UNH
SUPERNUS PHARMACEUTICALS, INC.
HCA vs SUPN
Sage Therapeutics, Inc.
HCA vs SAGE
Jazz Pharmaceuticals plc
HCA vs JAZZ
Alkermes plc.
HCA vs ALKS
Harmony Biosciences Holdings, Inc.
HCA vs HRMY
Krystal Biotech, Inc.
HCA vs KRYS
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe HCA's earnings power and valuation discipline deserve a lower multiple than the DCF range implies, then hold or add selectively; if you expect ACAD-like growth and margin expansion to persist, then HCA looks less attractive because the current price sits above the P/E-implied value of $315.45.
HCA's current price of $406.61 is below the DCF range midpoint and sits within the historical band, but it is above the P/E implied value of $315.45, indicating downside on an earnings-multiple basis. The relative valuation looks mixed because HCA is much cheaper than ACAD on P/E, P/S, EV/EBITDA, and EV/Revenue, yet ACAD's growth and margin profile is stronger in several headline metrics.
Supporting Metrics
